The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb/Medarex; EMD Serono; Foundation Medicine; Gilead Sciences; Merck; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Janssen Oncology; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Yasuhisa Fujii
Honoraria - MSD
 
Michiel Simon Van Der Heijden
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - 4SC (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche
 
Andrew James Weickhardt
Honoraria - Eisai; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; MSD
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; IPSEN,; MSD
 
Nicholas D. James
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; EUSA pharma; Janssen; pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ferring; Janssen Oncology; Merck; Pierre Fabre; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Janssen; Sanofi
 
Shahrokh F. Shariat
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Cepheid; Ferring; IPSEN,; Janssen; Lilly; MSD; Olympus; Pfizer; Pierre Fabre; Richard Wolf; Roche; Sanochemia; Sanofi; Takeda; UroGen pharma
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; IPSEN,; Janssen; Lilly; MSD; Olympus; Pfizer; Pierre Fabre; Richard Wolf; Roche; Sanochemia; Sanofi; Takeda; UroGen pharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; IPSEN,; Janssen; Lilly; Movember Foundation; MSD; Olympus; Pfizer; Pierre Fabre; Richard Wolf; Roche; Sanochemia; Sanofi; Takeda; UroGen pharma
 
Jeff M. Michalski
No Relationships to Disclose
 
Kentaro Imai
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Xiao Fang
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Ekta Kapadia
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Neal D. Shore
Employment - GenesisCare
Leadership - Alessa Therapeutics; Photocure
Consulting or Advisory Role - Abbvie; AIkido Pharma; Amgen; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clarity Pharmaceuticals; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Fize Medical; Foundation Medicine; Genesis Cancer Care; Genzyme; Guardant Health; ImmunityBio; Incyte; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myovant Sciences; Myriad Genetics; NGM Biopharmaceuticals; Nonagen Bioscience; Novartis; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Photocure; PlatformQ Health; Profound Medical; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Telix Pharmaceuticals; Tempus; Tolmar; Urogen pharma; Vaxiion; Vessi Medical
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
Expert Testimony - Ferring
Other Relationship - Alessa Therapeutics; Photocure